TANGO THERAPEUTICS IN

Tango Therapeutics Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients With MTAP-deleted Glioblastomas and Other Solid Tumors

21 май 2025 04:00:00 Источник Nasdaq GlobeNewswire

Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

12 май 2025 04:00:01 Источник Nasdaq GlobeNewswire

Tango Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

01 май 2025 04:00:00 Источник Nasdaq GlobeNewswire

Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline with Five Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025

25 мар 2025 13:30:00 Источник Nasdaq GlobeNewswire

Tango Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Highlights 

27 фев 2025 04:00:00 Источник Nasdaq GlobeNewswire

Tango Therapeutics to Present at Three Upcoming Investment Bank Conferences

20 фев 2025 04:30:00 Источник Nasdaq GlobeNewswire

Tango Therapeutics to Present at the Guggenheim SMID Cap Biotechnology Conference

30 янв 2025 04:00:00 Источник Nasdaq GlobeNewswire

Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2024

05 мар 2024 13:47:49 Источник Nasdaq GlobeNewswire

Tango Therapeutics to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

31 янв 2024 04:00:00 Источник Nasdaq GlobeNewswire

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 янв 2024 13:05:00 Источник Nasdaq GlobeNewswire

Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG348 in Patients with BRCA1/2-Mutant and Other HRD+ Cancers

03 янв 2024 04:00:00 Источник Nasdaq GlobeNewswire

Tango Therapeutics to Highlight Preclinical Data on PRMT5 Inhibitors at the Society for Neuro-Oncology (SNO) 28th Annual Meeting

13 ноя 2023 04:00:00 Источник Nasdaq GlobeNewswire

Tango Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Highlights

08 ноя 2023 04:00:01 Источник Nasdaq GlobeNewswire

Tango Therapeutics to Present at the Jefferies London Healthcare Conference

07 ноя 2023 04:00:00 Источник Nasdaq GlobeNewswire

Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

18 сен 2023 04:00:00 Источник Nasdaq GlobeNewswire

Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG348, a Novel USP1 Inhibitor for the Treatment of BRCA1/2-mutant and Other HRD+ Cancers

06 сен 2023 04:00:00 Источник Nasdaq GlobeNewswire

Tango Therapeutics Announces Updates to Its Board of Directors

29 авг 2023 14:08:05 Источник Nasdaq GlobeNewswire

Tango Therapeutics Announces $80 million Private Placement Financing

10 авг 2023 04:00:19 Источник Nasdaq GlobeNewswire

Tango Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Highlights

07 авг 2023 04:00:00 Источник Nasdaq GlobeNewswire

Tango Therapeutics Announces First Patient Dosed in TNG462 Phase 1/2 Trial in Patients With MTAP-deleted Solid Tumors

10 июл 2023 04:00:00 Источник Nasdaq GlobeNewswire